Loading...
  • visceral
  • The cause of excess subcutaneous and visceral fat deposition in an individual is the cumulative effect of an imbalance between the energy of ingested. (slideplayer.com)
  • 2  The cause of excess subcutaneous and visceral fat deposition in an individual is the cumulative effect of an imbalance between the energy of ingested food and that expended in the course of daily activities  Essentially, the deposition of fat is an adaptive physiologic process of energy storage that became maladaptive when technological advances altered the balance between the availability of food and the body's expenditure of energy. (slideplayer.com)
  • This fat is called visceral fat. (healthline.com)
  • Instead, visceral fat is stored deep inside the abdominal cavity around the internal organs. (healthline.com)
  • Visceral fat is associated with many serious health problems, from metabolic problems to increased risk of heart disease and type 2 diabetes. (healthline.com)
  • Safety indices, fasting insulin and glucose levels, visceral [AS PER AMENDMENT 02/05/02: and subcutaneous abdominal] fat are assessed. (clinicaltrials.gov)
  • Some studies actually dispute that there is a problem, and say that people with HIV do not have more visceral fat than HIV-negative people. (thebody.com)
  • The problems associated with increased visceral fat include poor body image, depression , bloating, fatigue , sleep apnea (breathing problems), and possible heart problems. (thebody.com)
  • The Multicenter AIDS Cohort Study (MACS) recently reported that men with HIV in general weigh less than HIV-negative men, but their visceral fat is about the same. (thebody.com)
  • Several studies report that people starting standard HIV combinations have an average increase in visceral fat of 15% after 96 weeks. (thebody.com)
  • An analysis of people in the French APROCO study found that those who started HIV meds with lower CD4 counts gained more visceral fat, possibly due to the large change in their CD4 counts. (thebody.com)
  • It was first thought that protease inhibitors were the main culprits of belly fat gain, but several studies that did not include protease inhibitors also showed increases in visceral fat. (thebody.com)
  • An analysis of a study comparing Aptivus to Kaletra showed that when taken with Viread and Epivir, the drugs did not increase visceral fat in those who start them with a CD4 count above 250. (thebody.com)
  • Some other studies have shown that people who start a protease inhibitor or non-nucleoside along with Zerit, AZT, or Videx seem to have more visceral fat gain than those who start them with other nucleosides. (thebody.com)
  • Switching from a protease inhibitor to Sustiva or Viramune while taking Zerit or AZT has not helped in lowering visceral fat. (thebody.com)
  • But a recent small study showed that people who switched from Kaletra to Reyataz while taking Truvada had a decrease of 15% in visceral fat after 6 months. (thebody.com)
  • This may be a part of the puzzle, but not the entire explanation for visceral fat gain. (thebody.com)
  • Unlike subcutaneous fat that lies just under your skin and is noticeable, visceral fat lies in your abdominal cavity, under the abdominal muscle, and often surrounds your vital organs. (mercola.com)
  • Visceral fat , together with elevated blood pressure, unstable blood sugar and unhealthy levels of cholesterol make up what we call "metabolic syndrome," which in turn increases your risk of heart disease, diabetes and stroke. (mercola.com)
  • Like all body fat, diet and exercise will help keep your visceral fat levels to a minimum, however there appear to be other factors involved as well, including the health of your digestive tract. (mercola.com)
  • New research from Sweden has uncovered a novel connection between intestinal permeability (aka leaky gut) and visceral fat. (mercola.com)
  • Women with higher markers of leaky gut also had higher levels of visceral fat and liver fat, and larger waist circumference, which suggests that this condition may promote the accumulation of visceral fat, as well as impact the related metabolic dysfunction. (mercola.com)
  • Because it means you, too, could have a leaky gut that is predisposing you to carry higher levels of visceral fat, which in turn could increase your risk of diabetes, heart disease and other chronic diseases. (mercola.com)
  • metabolism
  • Fortunately, the HIV meds most often linked to these problems are no longer commonly used, and newer meds are less likely to lead to changes in body shape and fat metabolism. (thebody.com)
  • onset
  • Patients usually present with diarrhea mixed with blood and mucus, of gradual onset that persists for an extended period (weeks). (wikipedia.org)
  • patients
  • This study investigates the use of metformin and rosiglitazone, a member of the thiazolidinedione class, in HIV-infected patients with hyperinsulinemia and central fat accumulation. (clinicaltrials.gov)
  • changes
  • AS PER AMENDMENT 02/05/02: A mid-thigh measurement was added to the study as a secondary endpoint to look for changes in extremity subcutaneous fat from therapy with rosiglitazone. (clinicaltrials.gov)